Effects of esketamine, remifentanil and lidocaine on withdrawal response of rocuronium in pediatrics: a prospective randomized placebo-controlled double-blind study

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2100050618

Enrollment

Unknown

Registered

2021-09-01

Start date

2021-09-20

Completion date

Unknown

Last updated

2022-05-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

pediatric anesthesia

Interventions

Experimental group1:esketamine

Experimental group2:remifentanil

Experimental group3:lidocaine

Control group:Normal saline

Eligibility

Sex/Gender

All

Age

3 Years to 12 Years

Inclusion criteria

Inclusion criteria: 1. Patients undergoing elective surgery under general anesthesia; 2. ASA level I-II; 3. Patients aged 3 to 12 years and singed informed consent form by their guardians; 4. Body Mass Index (BMI) 18.5 - 24.5.

Exclusion criteria

Exclusion criteria: 1. The patient whose guardians have not signed the informed consent; 2. Poor venous access, vasculitis, and previous thrombosis; 3. Predictable difficult airway; 4. Patients with liver, kidney and other organ dysfunction, abnormal coagulation function or mental illness before surgery; 5. Allergic to general anesthesia drugs, history of malignant high fever or family history.

Design outcomes

Primary

Measure	Time frame
withdrawal response;	—

Secondary

Measure	Time frame
heart rate;mean arterial pressure;Skin erythema;	—

Countries

China

Contacts

Public ContactLi Chuiyu

The Second Afliated Hospital of Fujian Medical University

839033687@qq.com+86 18396129125

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026